These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34292097)

  • 1. The role of amikacin in the treatment of nontuberculous mycobacterial disease.
    Raaijmakers J; Schildkraut JA; Hoefsloot W; van Ingen J
    Expert Opin Pharmacother; 2021 Oct; 22(15):1961-1974. PubMed ID: 34292097
    [No Abstract]   [Full Text] [Related]  

  • 2. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.
    Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
    Khan O; Chaudary N
    Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
    van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
    Ruth MM; Koeken VACM; Pennings LJ; Svensson EM; Wertheim HFL; Hoefsloot W; van Ingen J
    J Antimicrob Chemother; 2020 Mar; 75(3):609-617. PubMed ID: 31886864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
    Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
    Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720.
    Winthrop KL; Flume P; Hamed KA
    Expert Rev Anti Infect Ther; 2023; 21(11):1177-1187. PubMed ID: 37862563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
    Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
    Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W
    Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454
    [No Abstract]   [Full Text] [Related]  

  • 10. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
    Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Kim DH; Zo S; Kim SY; Jhun BW
    Ann Lab Med; 2024 Jan; 44(1):92-96. PubMed ID: 37665290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection.
    Rose SJ; Neville ME; Gupta R; Bermudez LE
    PLoS One; 2014; 9(9):e108703. PubMed ID: 25264757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Efficacy of Free and Nanoparticle Formulations of Gallium(III) meso-Tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and Gallium Biodistribution in Mice.
    Choi SR; Britigan BE; Switzer B; Hoke T; Moran D; Narayanasamy P
    Mol Pharm; 2018 Mar; 15(3):1215-1225. PubMed ID: 29421865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sudapyridine (WX-081) antibacterial activity against
    Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y
    mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.
    Chu HS; Chang SC; Shen EP; Hu FR
    PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D; Lange C
    Pneumologie; 2020 Nov; 74(11):773-779. PubMed ID: 33202438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
    Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
    Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.
    Olivier KN; Shaw PA; Glaser TS; Bhattacharyya D; Fleshner M; Brewer CC; Zalewski CK; Folio LR; Siegelman JR; Shallom S; Park IK; Sampaio EP; Zelazny AM; Holland SM; Prevots DR
    Ann Am Thorac Soc; 2014 Jan; 11(1):30-5. PubMed ID: 24460437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.
    Pennings LJ; Ruth MM; Wertheim HFL; van Ingen J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.